CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel

Opinion
Video

Panelists discuss how patient selection criteria and individual characteristics help determine whether ide-cel or cilta-cel is the more appropriate chimeric antigen receptor T-cell therapy choice for early-line treatment in patients with multiple myeloma.

Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
5 experts in this video
5 experts in this video
Related Content